기업 정보 불러오는 중
Just reported
Q3 2026 results
From Neuropace's results release of 2026년 11월 12일. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
US$23.1M
-16% y/y
+1.2% q/qGuided
—
No guide given
Operating income, adjusted
Actual
US$400K
Guided
—
No guide given
Company outlook
Full year 2026
- RevenueUS$91M – US$92M-8.5% y/y Lowered -9.0%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Neuropace is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$131.6BA+
SYKStryker Corp.US$117.9BA+
EWEdwards Lifesciences CorporationUS$61.6BA+
GEHCGE Healthcare Technologies Inc.US$37.5BA
GKOSGlaukos CorpUS$14.5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
MCKMckesson Corporation2026년 11월 4일BAGraded B, now A
CVSCVS Health Corp2026년 11월 4일BAGraded B, now A- EWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now A
- GEHCGE Healthcare Technologies Inc.2026년 10월 28일CAGraded C, now A
Neuropace, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
